The Technical Analyst
Enochian Biosciences Inc [ENOB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Enochian Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.79% $0.713
America/New_York / 4 aug 2023 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 45.38 mill |
| EPS: | -2.07 |
| P/E: | -0.344 |
| Earnings Date: | Mar 08, 2023 |
| SharesOutstanding: | 63.70 mill |
| Avg Daily Volume: | 0.255 mill |
| RATING 2023-08-29 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.344 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -0.344 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.41 - 2.79 ( +/- 7.42%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-23 | Miller Avram | Buy | 1 000 000 | Common Stock |
| 2023-10-23 | Miller Avram | Buy | 27 147 | Option to purchase shares of common stock |
| 2023-10-11 | Miller Avram | Buy | 0 | |
| 2023-10-04 | Hendriks Ruud | Buy | 16 129 | Option to purchase shares of common stock |
| 2023-10-04 | Boeren Leni | Buy | 16 129 | Option to purchase shares of common stock |
| INSIDER POWER |
|---|
| 90.82 |
| Last 80 transactions |
| Buy: 35 900 381 | Sell: 26 846 213 |
Forecast:
01:40 - $1.119
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.713 (1.79% ) |
| Volume | 0.0873 mill |
| Avg. Vol. | 0.255 mill |
| % of Avg. Vol | 34.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENOB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ENOB
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Latest Press Releases
2021-10-18 07:00:00 - Press Release
Enochian Biosciences Announces The Successful Completion Of An fda Pre-ind For A Potential Cure For Hiv: The Second Pre-ind In 1 Month
Company encouraged by clear path to ind in near-term following its review of the fda's center for biologics evaluation and research written comments company encouraged by clear path to ind in near-term following its review of the fda's center for biologics evaluation and research written comments
2021-10-15 18:00:00 - Press Release
Scientific Advisory Board Member Resigns Due To conflict With Responsibilities With Important Public Sector Entity
Los angeles, oct. 15, 2021 (globe newswire) -- (nasdaq: enob) – enochian biosciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that dr. peter piot has resigned as chairperson of the respiratory diseases scientific advisory board due to important responsibilities advising a major governmental organization on covid-19 that creates a conflict.
2021-10-12 18:00:00 - Press Release
Fireside Chat With Enochian Biosciences' ceo, Dr. Mark Dybul At h.c. Wainwright 2nd Annual hepatitis B Virus (hbv) Conference
Los angeles, oct. 12, 2021 (globe newswire) -- (nasdaq: enob) − enochian biosciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming h.c. wainwright global life sciences conference.
2021-09-27 07:00:00 - Press Release
Enochian Biosciences Announces Its successful Completion Of fda Pre-ind For A Potential Cure For hepatitis B Virus Infection
Company encouraged by clear path following review of fda's cber written comments company encouraged by clear path following review of fda's cber written comments
2021-08-30 07:00:00 - Press Release
Distinguished Scientific And Public Health Leaders To Join Enochian Biosciences' Scientific Advisory Board For Potential Inhaled Treatment And Prevention Of All Covid-19 And Influenza Variants
Los angeles, aug. 30, 2021 (globe newswire) -- (nasdaq: enob) – enochian biosciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a scientific advisory board (sab) focused on potential inhaled treatment and prevention of any current or future variants of sars-cov-2 – the virus that causes covid-19 – and influenza.
Latest News
2022-06-01 15:32:03 - Benzinga
'Murder-For-Hire Conspiracy': Why Enochian Biosciences Stock Is Plunging
Enochian Biosciences Inc (NASDAQ: ENOB) shares are trading lower Wednesday after Hindenburg Research issued a bearish report on the company. Last week, federal prosecutors announced the arrest of two men being charged in a "murder-for-hire" conspiracy, which resulted in the.
2022-05-26 17:30:54 - InvestorPlace
ENOB Stock Gains 20% Following Founder Arrest, Hindenburg Short
Enochian Bioscience is in the green today following the shocking arrest of the company founder earlier this week. ENOB stock closed up 20%.
2022-05-25 17:31:04 - Benzinga
6 Stocks Halted In Wednesday's Session: Here's Why
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.
2021-10-18 08:33:54 - Pulse2
ENOB Stock: Why The Price Increased Today
The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 3% pre-market today. This is why it happened.
2021-10-18 07:00:00 - GlobeNewsWire
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments
2021-10-15 18:00:00 - GlobeNewsWire
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict.
2021-10-12 18:00:00 - GlobeNewsWire
Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.
2021-09-27 07:00:00 - GlobeNewsWire
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
Company encouraged by clear path following review of FDA's CBER written comments Company encouraged by clear path following review of FDA's CBER written comments
2021-08-30 07:00:00 - GlobeNewsWire
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a Scientific Advisory Board (SAB) focused on potential inhaled treatment and prevention of any current or future variants of SARS-CoV-2 – the virus that causes COVID-19 – and Influenza.
2021-08-23 10:18:00 - GlobeNewsWire
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board
LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has joined the Scientific Advisory Board for a potential cure for Hepatitis B Virus (HBV), that causes liver disease in approximately 350 million people globally and 1 million deaths every year.